chronic kidney disease stages 3 and 4, defined by a eGFR of 15-60 ml min
Conditions
Interventions
Statin therapy will consist of a once daily dosis of 40 mg Atorvastatine for 3 months
Sponsors
Academical Medical Center
Eligibility
Inclusion criteria
Inclusion criteria: 1. Aged 50 years or older 2. CKD stages 3 and 4 (eGFR: 15-60 ml/min per 1.73m2) 3. Not receiving lipid lowering therapy
Exclusion criteria
Exclusion criteria: 1. Malignant diseases or any clinically significant medical condition that could interfere with the conduct of the study in the opinion of the investigator. 2. Standard contra-indications to 18F-FDG PET, and CT based on physicians experience and current practices 3. Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study. 4. Planned radiation exposure in the next year due to participation in a research project with radiation exposure or for clinical reasons. 5. Clinical signs of acute infection and/or CRP>10 6. History of MI/Stroke or known coronary artery disease 7. Already receiving lipid lowering treatment 8. Treatment with dialysis or renal transplantation 9. Treatment with CYP3A4 inhibitors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the anti-inflammatory effects of 3 months statin therapy on vessel wall inflammation by means of FDG PET/CT in patients with CKD. | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess differences in the innate immune system in patients with CKD before and after treatment with statins. | — |
Contacts
Public ContactR.M. Hoogeveen
AMC
Outcome results
None listed